Science Explorer Back to mapMap
Discussion
Institution · Infusion Associates

Most cited papers from Infusion Associates

Infusion Associates

What are the most cited papers from Infusion Associates?

The most cited paper from Infusion Associates is "Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat" (Dominique Paul Germain et al., 2016), with 566 citations. Next come "Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study" (395) and "Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study" (81).

Showing 29 of 29 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat Dominique Paul Germain et al. · New England Journal of Medicine Open access 10 Aug 2016 566
2 Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study Derralynn A. Hughes et al. · Journal of Medical Genetics Open access 10 Nov 2016 395
3 Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study Ulla Feldt‐Rasmussen, Derralynn A. Hughes, Gere Sunder–Plassmann et al. · Molecular Genetics and Metabolism Open access 15 Aug 2020 81
4 Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease Laura E. Case, Carl Bjartmar, Claire L Morgan et al. · Neuromuscular Disorders Open access 20 Dec 2014 59
5 Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study Eric L Wallace et al. · Journal of Medical Genetics Open access 8 Nov 2023 49
6 Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease Özlem Göker-Alpan, Michael J. Gambello, Gustavo H. B. Maegawa et al. · JIMD Reports Book chapterOpen access 2015 30
7 Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa Özlem Göker-Alpan, Khan J. Nedd, Suma P. Shankar et al. · JIMD Reports Book chapterOpen access 2015 18
8 Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta. Renuka Pudi Limgala, Tabitha Jennelle, Matthew L. Plassmeyer et al. · PubMed Open access 2019 16
9 Targeting Job Retention Services for Welfare Recipients Anu Rangarajan, Peter Z. Schochet, Dexter Chu Book chapterOpen access Sep 2002 9
10 Once every 4 weeks - 2 mg/kg of pegunigalsidase alfa for treating Fabry disease Preliminary results of a phase 3 study Myrl D. Holida, John A. Bernat, Nicola Longo et al. · Molecular Genetics and Metabolism Feb 2019 8
11 Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study) Bincy P Abraham, Bertus Eksteen, Khan J. Nedd et al. · Advances in Therapy Open access 16 Mar 2022 7
12 eP149: Safety and efficacy of pegunigalsidase alfa, every 4 weeks, in Fabry disease: Results from the phase 3, open-label, BRIGHT study John A. Bernat, Myrl D. Holida, Nicola Longo et al. · Genetics in Medicine Open access Mar 2022 7
13 Evaluating Changes in del Nido Cardioplegia Practices in Adult Cardiac Surgery Donald S. Likosky, Xiaoting Wu, David C Fitzgerald et al. · Journal of ExtraCorporeal Technology Open access Sep 2020 6
14 Compartment Syndrome of the Hand Secondary to Intravenous Extravasation. Cara M Barber, Matthew P. Fahrenkopf, Nicholas S. Adams et al. · PubMed Open access 2018 3
15 Embedding IP Unique Shortest Path Topology on a Wavelength-Routed Network: Normal and Survivable Design Gaurav Agrawal, Deep Medhi · IEEE/ACM Transactions on Networking 20 Apr 2015 3
16 P-545. Feasibility, Fidelity, and Effectiveness of Administering CABENUVA in Infusion Centers Cassidy A. Gutner, Conn M. Harrington, Gilda Bontempo et al. · Open Forum Infectious Diseases Open access 29 Jan 2025 2
17 Analysis of the baseline characteristics of Fabry disease patients screened for the pegunigalsidase alfa phase III BALANCE study David G. Warnock et al. · Molecular Genetics and Metabolism Open access Feb 2019 2
18 A Phase 4 Study to Evaluate the Safety and Tolerability of Higher Infusion Rates of Agalsidase Beta to Shorten Infusion Duration in Fabry Disease: Interim Analysis Maryam Banikazemi, Özlem Göker-Alpan, Khan J. Nedd et al. · Journal of the American Society of Nephrology Oct 2024 1
19 Feasibility, Fidelity, and Effectiveness of Administering Long-Acting Cabotegravir + Rilpivirine in Infusion Centers in the United States: Findings From the Phase 4 GLACIER Implementation Study Cassidy A. Gutner, Conn Harrington, Gilda Bontempo et al. · Journal of the International Association of Providers of AIDS Care (JIAPAC) Open access 2026 0
20 Additional file 1 of Explaining the Diffusion of Project ECHO James W. Dearing, R. Sam Larson · Figshare Open access 2025 0
21 Additional file 1 of Explaining the Diffusion of Project ECHO Dearing, James W., Larson, R. Sam · Figshare Open access 2025 0
22 #197 A phase 4 study to evaluate the safety and tolerability of higher infusion rates of agalsidase beta to shorten the infusion duration in Fabry disease—Preliminary data Maryam Banikazemi, Özlem Göker-Alpan, Khan J. Nedd et al. · Nephrology Dialysis Transplantation Open access Oct 2025 0
23 P236: Extending the interval between pegunigalsidase alfa infusions in patients with Fabry disease: Five-year interim results from the ongoing BRIGHT51 study John A. Bernat et al. · Genetics in Medicine Open Open access 2025 0
24 Prevalence of frailty in the elderly with rheumatoid arthritis Rodrigo Lozano-Lozano, David Vega‐Morales, Macarena del Rosario Sifuentes-Martinez et al. · ˜The œJournal of Latin American geriatric medicine Open access 5 Mar 2025 0
25 P511 Baseline characteristics of ulcerative colitis patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (01) Douglas C. Wolf et al. · Journal of Crohn s and Colitis 26 Jan 2017 0
26 Comparison of clinical practice guidelines and actual clinical practice in Fabry disease diagnosis Dawn A. Laney, Amy L White, Myrl D. Holida et al. · Molecular Genetics and Metabolism 27 Jan 2015 0
27 Evaluation of glycosphingolipid clearance in patients with Fabry disease treated with agalsidase alfa who switched to agalsidase beta (the INFORM study) John A. Barranger, Michael J. Gambello, Özlem Göker-Alpan et al. · Molecular Genetics and Metabolism 27 Jan 2014 0
28 HGT-REP-059 treatment protocol: effect and tolerability of open-label agalsidase alfa in patients with Fabry disease Özlem Göker-Alpan, Khan J. Nedd, Suma P. Shankar et al. · Molecular Genetics and Metabolism 27 Jan 2014 0
29 Anti-drug antibody findings of agalsidase alfa for Fabry Disease: Treatment-naïve or formerly treated with agalsidase beta Özlem Göker-Alpan, Khan J. Nedd, Suma P. Shankar · Molecular Genetics and Metabolism 26 Jan 2013 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.